Zydus Lifesciences Share Price Surges 6% Following Q4 Earnings Release
Zydus Lifesciences Shares Surge 6% on Strong Q4FY26 Earnings and Share Buyback Plan
On Wednesday, 20 May, the share price of Zydus Lifesciences surged over 6% following the company's robust Q4FY26 earnings and the announcement of a share buyback plan. The pharmaceutical major reported a significant increase in consolidated net profit, rising by 14.6% year-on-year to ₹1,592.9 crore for the quarter ended 31 March. This growth was primarily driven by the strong performance of its consumer wellness business.
The company's revenue from operations rose to ₹7,587 crore from ₹6,527.9 crore in the year-ago period, indicating a notable increase. Breaking down the revenue, the pharma business reported ₹5,643.6 crore, a 4.9% year-over-year rise. In contrast, the consumer wellness segment witnessed sharp growth, with revenue increasing to ₹1,463.3 crore from ₹908.1 crore a year ago.
The company's board has approved a share buyback worth up to ₹1,100 crore at ₹1,150 per share, pending shareholder approval. Additionally, the board has recommended a final dividend of Re 1 per equity share.
Read also: Expert Portfolio Manager Raja Venkatraman Names Top Investment Picks for June 4
| Segment | Q4FY26 Revenue | Q4FY25 Revenue | Year-over-Year Growth |
|---|---|---|---|
| Pharma Business | ₹5,643.6 crore | ₹5,400.7 crore | 4.9% |
| Consumer Wellness | ₹1,463.3 crore | ₹908.1 crore | Significant Growth |
Investor Takeaway
Investors should consider the positive earnings release and share buyback plan as a potential catalyst for the stock.
More in Market
Expert Portfolio Manager Raja Venkatraman Names Top Investment Picks for June 4
MarketSmith India's 4 June Stock Recommendations
Foreign Investors Outpace Domestic Mutual Funds in Rupee Returns Despite Record Withdrawal of $27 Billion
